Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or METamplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

MLA

Wu, Yi-Long, et al. “Tepotinib plus Gefitinib in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with MET Overexpression or METamplification and Acquired Resistance to Previous EGFR Inhibitor (INSIGHT Study): An Open-Label, Phase 1b/2, Multicentre, Randomised Trial.” The Lancet Respiratory Medicine, vol. 8, no. 11, Nov. 2020, pp. 1132–43. EBSCOhost, https://doi.org/10.1016/S2213-2600(20)30154-5.

APA

Wu, Y.-L., Cheng, Y., Zhou, J., Lu, S., Zhang, Y., Zhao, J., Kim, D.-W., Soo, R. A., Kim, S.-W., Pan, H., Chen, Y.-M., Chian, C.-F., Liu, X., Tan, D. S. W., Bruns, R., Straub, J., Johne, A., Scheele, J., Park, K., … Bui, L. (2020). Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or METamplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. The Lancet Respiratory Medicine, 8(11), 1132–1143. https://doi.org/10.1016/S2213-2600(20)30154-5

Chicago

Wu, Yi-Long, Ying Cheng, Jianying Zhou, Shun Lu, Yiping Zhang, Jun Zhao, Dong-Wan Kim, et al. 2020. “Tepotinib plus Gefitinib in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with MET Overexpression or METamplification and Acquired Resistance to Previous EGFR Inhibitor (INSIGHT Study): An Open-Label, Phase 1b/2, Multicentre, Randomised Trial.” The Lancet Respiratory Medicine 8 (11): 1132–43. doi:10.1016/S2213-2600(20)30154-5.